Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

NCT04144348 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Metapneumovirus and Human Parainfluenza Infection

Interventions

BIOLOGICAL: mRNA-1653
BIOLOGICAL: Placebo

Sponsor

ModernaTX, Inc.